From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2017 call → NOWe need answer YES/NO. Need analyze transcript. Question asks whether management describes recently crossed into approved/specified/listed/qualified/reimbursed/pre-authorized choice inside buyers' systems, so future business can arrive without discrete selling event, and conveys status new enough most volume ahead. Need parse transcript. Management discusses partnerships, CMS reimbursement, J code, commercial payers. Dave Stack: "We are currently working with CMS policymakers to achieve an off-cycle change around reimbursement practices that bundle EXPAREL within their fixed payment to outpatient and ambulatory surgical centers. In parallel, we are seeking a unique reimbursement code through the standard process with CMS. We applied in December and if we are granted a code it would take effect January 1, 2019. Around the middle of this year, CMS will publish a draft of their proposed rule to take effect the following year. We are working with CMS to have EXPAREL unbundled within that draft rule. Securing separate reimbursement for EXPAREL would create a significant opportunity for us. Commercial payers already recognize the economic advantage of reimbursing EXPAREL separately under C9290. They are supporting enhanced recovery after surgery protocols with EXPAREL and shifting many inpatient procedures to the outpatient setting, which is yielding a savings of roughly 40% per case." This is about reimbursement. But is it "recently crossed" into approved/listed? They are seeking, applied, if granted. Not yet. Commercial payers already recognize and reimburse under C9290. Is that a buyer-side system? C9290 is a HCPCS code? It exists. But management says "Commercial payers already recognize the economic advantage of reimbursing EXPAREL separately under C9290. They are supporting enhanced recovery after surgery protocols with EXPAREL and shifting many inpatient procedures to the outpatient setting." This suggests some payers already reimburse. But is it new? They are working to expand. The question asks if management conveys that company has recently crossed into being approved/specified/listed/qualified/reimbursed/pre-authorized choice inside buyers' own systems, so meaningful portion future business can arrive without discrete selling event, and status new enough most volume ahead. Need see if management says that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.